Rinit (ranitidine) coated tablets 150 mg. №100

Description

Rinit (ranitidine) coated tablets 150 mg. №100

Composition

active ingredient: ranitidine;

1 tablet contains ranitidine hydrochloride in terms of ranitidine 150 mg;

excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, coating Opadry II 85G53691 orange: polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide (E 171), FCF yellow (E 110), lecithin, Ponceau 4R (E 124), indigo carmine (E 132).

Medicinal form

Coated tablets.

Main physico-chemical properties: round biconvex tablets covered with an orange shell.

Pharmacotherapeutic group

Means for the treatment of peptic ulcer and gastroesophageal reflux disease. Antagonists of H2-histamine receptors.
Code ATX A02B A02.

Pharmacological properties

It is a remedy for digestive disorders. It blocks histamine H2 receptors, decreasing the production of hydrochloric acid in the stomach. This leads to an increase in the pH of the gastric contents, a decrease in the activity of pepsin.

Indications

Rinit is used for indigestion, characterized by stomach or chest pain. It is also used to treat and prevent the development of gastric ulcer, duodenal ulcer, lesions of the gastric mucosa caused by medication (NSAID-gastropathy), excessive secretion of gastric juice. It is indicated for symptomatic and stress ulcers, erosive inflammation of the esophagus (esophagitis), reflux esophagitis, Zollinger-Ellison syndrome, systemic mastocytosis (urticaria pigmentosa), multiple adenomas (polyendocrine adenomatosis).

Contraindications

Rinit is contraindicated in case of allergy to components, the presence of malignant tumors of the stomach, cirrhosis of the liver with portosystemic encephalopathy in the past, severe renal failure, pregnancy. It is prescribed with caution in case of impaired renal function, acute porphyria (violation of pigment metabolism).
Not assigned to children under 16 years of age.

Application during pregnancy and lactation

Rinit should not be used during the indicated periods.

Method of administration and dosage

Rinit tablets are used orally.
The standard dose is one tablet (300 mg) per day.
The tablet must be swallowed whole, washed down with a little water.
The duration of treatment is 2–4 weeks.
If symptoms do not disappear within 2 weeks of treatment, you should consult a doctor.
In case of impaired renal function (creatinine clearance rate less than 50 ml / minute), dose adjustment is required.
It should be borne in mind that hemodialysis reduces the concentration of ranitidine in the serum. Patients on dialysis should take the drug immediately after the procedure.

Overdose

Overdose symptoms: convulsions, bradycardia (slow heartbeat), ventricular arrhythmia.
Treatment for an overdose depends on the symptomatology. With the development of seizures, diazepam is prescribed, with bradycardia, ventricular arrhythmia – lidocaine, atropine.
Hemodialysis can be performed.

Side effects

Possible violations of hematopoiesis (leukopenia, agranulocytosis, thrombocytopenia, pancytopenia, hypo / aplasia of the bone marrow, hemolytic anemia), disorders of the digestive system (constipation, dry mouth, nausea, loose stools, abdominal pain, increased activity of liver enzymes, hepatitis, pancreatitis ), the work of the heart (decreased pressure, arrhythmia, bradycardia, AV blockade, cardiac arrest), the nervous system (dizziness, fatigue, headache, drowsiness, confusion, irritability, tinnitus, hallucinations, involuntary movements), sensory organs (fuzziness vision, paresis of accommodation), musculoskeletal system (pain in muscles, joints), allergic reactions (skin rashes, urticaria, angioedema, bronchospasm, anaphylactic shock, erythema multiforme), endocrine system disorders (gynecomastia, absence of menstruation, decreased potency, hyperprolactinemia), hair loss (alopecia), increased activity of glutamate transpeptidase, acute porphyria, hypercreatininemia.